|
|
|
|
| LEADER |
01000caa a22002652 4500 |
| 001 |
NLM291739024 |
| 003 |
DE-627 |
| 005 |
20250224123452.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231225s2019 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2018.12.006
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n0972.xml
|
| 035 |
|
|
|a (DE-627)NLM291739024
|
| 035 |
|
|
|a (NLM)30543921
|
| 035 |
|
|
|a (PII)S1521-6616(18)30714-9
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Gomes, João Pedro
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Intravenous immunoglobulin (IVIG) in the vanguard therapy of Systemic Sclerosis
|
| 264 |
|
1 |
|c 2019
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 02.12.2019
|
| 500 |
|
|
|a Date Revised 02.12.2019
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2018 Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a Systemic Sclerosis (SSc) is a rare autoimmune disease that is characterized by a progressive skin fibrosis, an obliteration of the microvasculature and an exaggerated extracellular matrix deposition, which lead to a multisystemic dysfunction. Various pathogenetic mechanisms were described. The lack of a successful therapy make SSc a disease with a poor prognosis. The intravenous immunoglobulin (IVIG) has been used for a long time in different autoimmune diseases, and firstly used in SSc patients in 2000. IVIG has multiple non-specific mechanisms of action and, beyond an impressive improvement in muscle symptoms, a French nationwide cohort demonstrated that IVIG ameliorates the skin disease and systemic inflammation, and helps the daily dose corticosteroid's tapering at the end of the treatment. The benefits on gastrointestinal symptoms of IVIG was reported by a recent English article, in which the patients consistently reported a decrease in the gastro-esophageal reflux disease symptoms and their frequencies. The impact on the lung involvement still remains unclear. One of the advantages of IVIG is its safe profile. Few adverse effects were reported and most of them are mild, and can be managed and usually they do not relapse. Harmful effects were described, but they can be avoid with cautious and judicious use of this therapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Autoimmune diseases
|
| 650 |
|
4 |
|a Autoimmunity
|
| 650 |
|
4 |
|a Fibrosis
|
| 650 |
|
4 |
|a Intravenous immunoglobulins (IVIG)
|
| 650 |
|
4 |
|a Systemic sclerosis
|
| 650 |
|
7 |
|a Immunoglobulins, Intravenous
|2 NLM
|
| 700 |
1 |
|
|a Santos, Lèlita
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Shoenfeld, Yehuda
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 199(2019) vom: 25. Feb., Seite 25-28
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:199
|g year:2019
|g day:25
|g month:02
|g pages:25-28
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2018.12.006
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 199
|j 2019
|b 25
|c 02
|h 25-28
|